KANSAS CITY, Kan., June 2, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will participate in two upcoming investor conferences.
Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, will provide an overview of the Company's business during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
|
Event: |
William Blair 35th Annual Growth Stock Conference | |
|
Date: |
Tuesday, June 9, 2015 | |
|
Time: |
8:50 a.m. (Central Time) | |
|
Location: |
The Four Seasons Hotel, Chicago, IL |
|
Event: |
JMP Securities Life Sciences Conference 2015 | |
|
Date: |
Tuesday, June 23, 2015 | |
|
Time: |
1:00 p.m. (Eastern Time) | |
|
Location: |
The St. Regis New York, New York, NY |
The presentations will be webcast live and remain available for 30 days following the presentation. To access the webcast, please visit the investor relations section of the Aratana website at aratana.investorroom.com.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts:
For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1026
For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694
SOURCE Aratana Therapeutics, Inc.